Cardioprotective effects of Commiphora mukul against isoprenaline-induced cardiotoxicity: a biochemical and histopathological evaluation.

Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 110 029, India.
Journal of Environmental Biology (Impact Factor: 0.55). 11/2011; 32(6):731-8.
Source: PubMed

ABSTRACT Commiphora mukul commonly known as Guggul is one of the oldest and commonly consumed herb for promoting heart and vascular health. Present study was undertaken to evaluate cardioprotective potential of Commiphora mukul against isoprenaline-induced myocardial necrosis in rats. Wistar albino rats were divided into three main groups: sham (saline only), isoprenaline control (saline and isoprenaline) and Commiphora mukul treated (Commiphora mukul and isoprenaline) groups. Commiphora mukul was administered in three doses 100, 200 and 400 mg kg(-1) p.o. for 30 days. On 29th and 30th day, the animals of isoprenaline control and Commiphora mukulpretreatment groups were administered isoprenaline (85 mg kg(-1); s.c.), consecutively at an interval of 24 hr. Isoprenaline administration produced a significant (p < 0.05) decrease in myocardial antioxidants; superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSHPx), reduced glutathione (GSH), and myocyte injury marker enzymes creatine-phosphokinase-MB (CK-MB) and lactate dehydrogenase (LDH) along with enhanced lipid peroxidation; malondialdehyde (MDA) in heart. Commiphora mukul pretreatment reversed the isoprenaline-induced oxidative changes in rat myocardium by significant (p < 0.05) increase in SOD, CAT, GSHPx, GSH and reduction of MDA. In addition to improving myocardial antioxidant status, Commiphora mukul also prevented the leakage of LDH and CK-MB from heart. Further, histopathological examination showed the reduction of necrosis, edema and inflammation following Commiphora mukul pretreatment. Based on present findings, it is concluded that Commiphora mukul may be a potential preventive and therapeutic agent against the oxidative stress associated ischemic heart disease owing to antioxidant and antiperoxidative activity.

  • [Show abstract] [Hide abstract]
    ABSTRACT: : Biodiversity contributes significantly towards human livelihood and development and thus plays a predominant role in the well being of the global population. According to WHO reports, around 80 % of the global population still relies on botanical drugs; today several medicines owe their origin to medicinal plants. Natural substances have long served as sources of therapeutic drugs, where drugs including digitalis (from foxglove), ergotamine (from contaminated rye), quinine (from cinchona), and salicylates (willow bark) can be cited as some classical examples.Drug discovery from natural sources involve a multifaceted approach combining botanical, phytochemical, biological, and molecular techniques. Accordingly, medicinal-plant-based drug discovery still remains an important area, hitherto unexplored, where a systematic search may definitely provide important leads against various pharmacological targets.Ironically, the potential benefits of plant-based medicines have led to unscientific exploitation of the natural resources, a phenomenon that is being observed globally. This decline in biodiversity is largely the result of the rise in the global population, rapid and sometimes unplanned industrialization, indiscriminate deforestation, overexploitation of natural resources, pollution, and finally global climate change.Therefore, it is of utmost importance that plant biodiversity be preserved, to provide future structural diversity and lead compounds for the sustainable development of human civilization at large. This becomes even more important for developing nations, where well-planned bioprospecting coupled with nondestructive commercialization could help in the conservation of biodiversity, ultimately benefiting mankind in the long run.Based on these findings, the present review is an attempt to update our knowledge about the diverse therapeutic application of different plant products against various pharmacological targets including cancer, human brain, cardiovascular function, microbial infection, inflammation, pain, and many more.
    Advances in biochemical engineering/biotechnology. 07/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Concerns about ethnicity-related differences have resulted in a significant “drug lag” in regulatory approvals. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) document on Ethnic Factors in the Acceptability of Foreign Clinical Data, ICH E5, provides guidelines for assessing ethnicity as a cause of differences in drug treatment and using bridging strategies to avoid unnecessary duplication of clinical trials without compromising the quality, safety, and efficacy of the drug, with the goal of expediting the drug approval process. However, these guidelines have not been fully adopted by all countries, and there are differences in the way the bridging concept is applied. An approach that may provide the resolution to this dilemma is the multi-regional parallel bridging method, or simultaneous drug development. However, the definition of ethnicity is currently too vague and imprecise for clinical trial data to be easily understood and extrapolated across borders. The integration of pharmacogenomics and biomarkers in drug development may provide greater clarity to the characterization of drug response variability between populations.
    Pharmacogenomics, Edited by Lam, Y.-W. F. & Cavallari, L. H., 01/2013: chapter 10- The Importance of Ethnicity Definitions and Pharmacogenomics in Ethnobridging: pages 367-404; Academic Press, San Diego., ISBN: 978-0-12-391918-2
  • Source

Full-text (2 Sources)

Available from
Oct 8, 2014